Overview of a roundtable on NHANES monitoring of biomarkers of folate and vitamin B-12 status: measurement procedure issues123456 by Yetley, Elizabeth A et al.
Overview of a roundtable on NHANES monitoring of biomarkers of
folate and vitamin B-12 status: measurement procedure issues
1–6
Elizabeth A Yetley, Paul M Coates, and Clifford L Johnson
ABSTRACT
A roundtable dialogue to discuss “NHANES Monitoring of Bio-
markers of Folate and Vitamin B-12 Status” took place in July
2010. This article provides an overview of the meeting and this sup-
plement issue. Although the focus of the roundtable dialogue was on
the measurement of folate and vitamin B-12 status biomarkers in
NHANES, this article also describes the relevance and importance
of these issues for clinical and research laboratories. The roundtable
identiﬁed the microbiological assay (MA) as the gold standard for
measurement of serum and red blood cell folate concentrations. The
roundtable noted that differences in results between the Bio-Rad
Quantaphase II procedure(Bio-Rad Laboratories, Hercules, CA)that
NHANES1991–1994and1999–2006usedandtheMAthatNHANES
2007–2010 used will require adjustment equations to evaluate time
trends. The roundtable found that the close agreement between the
serum results for the MA and liquid chromatography–tandem mass
spectrometry (LC-MS/MS) procedures supported the conversion to
LC-MS/MSforserumfolate infutureNHANES.The roundtable rec-
ognized the uncertainty about whether subclinical vitamin B-12 deﬁ-
ciency is a public health concern but encouraged reinstatement of at
leastonecirculatingvitaminB-12measureandonefunctionalvitamin
B-12statusmeasureinfutureNHANES.TheuseofserumvitaminB-
12andplasmamethylmalonicacidwouldprovidecontinuitywithpast
NHANES.TheroundtablesupportedthecontinueduseoftheNational
Institute of Standards and Technology (NIST) reference materials in
NHANES biomarker analyses and the further development of addi-
tional reference materials by the NIST. Am J Clin Nutr 2011;94
(suppl):297S–302S.
INTRODUCTION
Sincetheearly1970s,NHANEShaveprovidedinformationon
the nutritional and health status of the US population (1). Poli-
cymakers and researchers use the survey results to inform and
evaluate public health programs and policies, develop national
reference intervals for nutrient and health indexes, and generate
research hypotheses.
ScientistsoftenexpressNHANESresultsaspointestimates(eg,
for prevalence estimates of at-risk groups) and trends over time.
Therefore, the surveys require highly accurate measurement
procedures to ensure that cutoffs of nutrient adequacy and safety
derived from published literature or on the basis of commonly
accepted clinical guidelines are appropriate for the NHANES
context. Accurate measurement procedures are also necessary to
yield trends in estimates over time that can be attributed to real
changesinnutritionalstatusandarenotsimplyartifactsofchanges
in,orproblemswith,measurementprocedures.Giventhelongand
repetitive nature of NHANES, which started in 1971 and is still
ongoing, NHANES must also be responsive to changes in the
measurement of nutrient biomarkers that inevitably occur as sci-
ence evolves.
VariousNHANEShavemeasuredseveralfolate-andvitaminB-
12–relatedbiomarkersoverthepast3decades(Table1).Because
of the critical need for rigorous scientiﬁc standards for NHANES
measures within the context of a science base that changes con-
stantly, sponsoring agencies have periodically convened expert
panels to review the measurement of nutrient biomarkers in these
surveys (1). On 15–16 July 2010, the Ofﬁce of Dietary Supple-
ments (ODS) of the National Institutes of Health and the Division
of Health and Nutrition Examination Surveys of the National
Center for Health Statistics, Centers for Disease Control and
Prevention, convened the latest expert group, a roundtable to
discuss “NHANES Monitoring of Biomarkers of Folate and Vi-
taminB-12Status:MeasurementProcedureIssues.”Thepurposeof
thisroundtablewastoassessmeasurementprocedureissuesfor the
NHANES monitoring of biomarkers of folate and vitamin B-12
status, which included past, current, and future surveys. This
overview provides a roadmap for the background presentations
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followed these presentations during this workshop.
APPLICABILITY TO NON-NHANES SETTINGS
The focus of this roundtable was on the measurement and in-
terpretationofbiomarkersoffolateandvitaminB-12statuswithin
theNHANEScontext.However,we believethattheroundtable’s
review and discussion of the issues involved in the accurate
measurementofbiomarkersoffolateandvitaminB-12statushave
broad applicability to the clinical and research communities.
Different measurement procedures give different results for
many, if not all, nutrient biomarkers. The recent roundtable (2010
roundtable) reviewed examples of this challenge for folate- and
vitaminB-12–relatedbiomarkers(2,3);apreviousroundtable(2009
roundtable) reviewed these issues for serum 25-hydroxyvitamin D
(4).The2009roundtableconcluded,afteralengthydiscussion,that
alllaboratories(clinical,research,andpublichealth)shouldbeable
toproducenutrientbiomarkerresultsthatareaccurateandtraceable
tohigh-levelreferencemeasurementproceduresthatorganizations,
suchastheJointCommitteeforTraceabilityinLaboratoryMedicine,
recognize. For example, most clinical, research, and public health
laboratories compare their results with commonly accepted status
cutoffsandresultsinthepublishedliterature.Mostlaboratoriesneed
to be able to monitor changes accurately over time, regardless of
whetherthefocusisonindividualpatientsorgroups.Manypatients
undergotestingindifferentclinicsandlaboratoryfacilities,whichis
why accuracy (and comparability) of results is so important.
The 2009 and 2010 roundtables noted the urgent need for trials
thatrelatednutrientbiomarkerdatatoclinicaloutcomestoidentify
cutoffsofnutrientadequacythatminimizemisclassiﬁcationerrors
(2–4). However, meaningful progress in this area depends on the
abilitytoaccuratelymeasurebiomarkerconcentrationsinamanner
that is independent of measurement procedure, time, and labo-
ratory. This approach requires all laboratories to conduct their
measurements in a manner that is traceable to reference methods
and standards that national and international organizations rec-
ognize (4, 5).
The 2009 roundtable acknowledged that many clinical and
research laboratories lack sufﬁcient funding for, or the analytic
skills to use, expensive analytic equipment and to conduct high-
order measurement procedures. However, the roundtable also felt
strongly that laboratories must be familiar with 1) the urgent need
for measurement accuracy, 2) generally recognized performance
characteristics, and 3) available guidelines (4).
Oneofthebackgroundarticlesinthisjournalsupplementprovides
information on key concepts and guidelines for clinical laboratory
testing and how working laboratories that commonly use com-
mercialassaykitsorin-housemeasurementprocedurescanachieve
traceability (5). Other roundtable summaries in this supplement
provideinformationonperformancecharacteristicsoftheNHANES
measurement procedures (2, 3); many of these measurement pro-
cedures are also available to research and clinical laboratories.
Ultimately, commercial assay kit manufacturers will have primary
responsibilityforimprovementoftheirkits.However,expertpanels
suchasthe2009and2010roundtablesandlaboratoryscientistswho
askmanufacturersofcommercialkitsabouttheirkits’performance
and traceability characteristics will help move the science forward
and encourage manufacturers to make necessary improvements.
Aswithmeasurementprocedures,theissuesrelatedtotheuseand
interpretation of biomarkers of folate and vitamin B-12 status also
have broad applicability beyond NHANES contexts (1, 6–8). For
example,allusersofthesedataneedtounderstandwhatthedifferent
biomarkers reﬂect or measure. Users also need to understand the
derivation of cutoffs of status and to determine the relevance of
published or commonly used cutoffs to their own setting.
A major difference between epidemiologic research such as
NHANES and the use of folate and vitamin B-12 status bio-
markers in clinical settings is that clinical settings can often
evaluate biomarker results within the context of other signs and
symptoms, whereas NHANES often lacks such information.
However, the roundtable noted that identiﬁcation of subclinical
vitamin B-12 deﬁciency, whether in the clinical setting or in
epidemiologicresearch,dependscompletelyonconcentrationsof
biomarkers, such as serum vitamin B-12, plasma methylmalonic
acid (MMA), and total homocysteine (tHcy) because this con-
dition is asymptomatic (3, 7). In a discussion of an example of a
difference between epidemiologic and clinical settings, the round-
table members agreed that red blood cell (RBC) folate may not have
an advantage over serum folate concentrations for assessment of
the folate status of the US population in NHANES. However, the
roundtable pointed out that RBC folates are often necessary in
clinical settings where recent drastic changes in the folate intakes
of ill patients may rapidly affect serum folate concentrations (2).
In this situation, RBC folate would provide a better indication of
body stores than would serum folate.
AGENDA
Aplanningcommittee(PC)ofgovernmentscientistswhomeasure
and use NHANES folate- and vitamin B-12-related biomarkers and
academicians with expertise in the measurement and assessment of
folateandvitaminB-12statusdevelopedtheroundtableagenda
(Table 2) and identiﬁed panelists for the roundtable (see Table
S1 under “Supplemental data” in the online issue). The PC chose
roundtablepanelistswithabroadrangeofexpertisein,forexample,
laboratory science, epidemiology, biostatistics, folate and vitamin
B-12 assessment, clinical medicine, and NHANES use.
TABLE 1
Biomarkers of folate and vitamin B-12 status in NHANES
1
Biomarker Survey
Serum folate 1974–75, 1976–80, 1988–94, 1999–2010
RBC folate 1976–80, 1988–94, 1999–2010
Serum FA and 5-MTHF 1999–2002,
2 2007–2010
3
Serum vitamin B-12 1976–80, 1991–94, 1999–2006
Total homocysteine 1991–94,
4 1999–2006
Methylmalonic acid 1988–94,
5 1999–2004
1 RBC, red blood cell; FA, folic acid (also referred to as unmetabolized
folic acid); 5-MTHF, 5-methyltetrahydrofolic acid.
2 Based on a special research project using surplus sera that was con-
ducted at the Jean Mayer US Department of Agriculture Human Nutrition
Research Center on Aging at Tufts University, Boston, MA.
3 Based on a one-third subset research sample and a study conducted by
the National Center for Environmental Health at the Centers for Disease
Control and Prevention, Atlanta, GA.
4 Results from a special research project at Tufts University that used
surplus sera for persons aged 12 y.
5 Results from a special research project at Tufts University that used
surplus sera for adults aged 30–39 y and 65 y.
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expert panels have used (1), the PC organized the roundtable
meeting agenda to include a combination of background pre-
sentations and dialogue sessions. In past NHANES expert panel
meetings, the background presentations provided detailed des-
criptions of the NHANES measurement procedures (ie, quality
controls and performance characteristics) and crossover study
results,withappropriateadjustmentequationswhenmeasurement
procedures changed. The PC agreed that similar presentations by
ChristinePfeifferoftheNationalCenterforEnvironmentalHealth
(NCEH) at the Centers for Disease Control and Prevention in
Atlanta would be essential for the roundtable (Table 2). Pfeiffer
andhergrouphavebeenresponsibleforallthefolate-andvitamin
B-12–related biomarker measurements in NHANES, except for
several special research projects at Tufts University that used
surplusserafrompriorsurveys.Pfeiffer’spresentationsaddressed
the measurement of serum and RBC folates [which included an
interlaboratorystudyontheuseofamicrobiologicalassay (MA)
to measure serum and RBC folates (9)], serum vitamin B-12,
MMA, and tHcy in various NHANES (Table 1). Because Pfeiffer’s
information was the main focus of the roundtable dialogue, the
articles that describe the roundtable review summarize these
presentations (2, 3).
The PC also beneﬁted from lessons learned from the 2009
roundtable on the measurement of serum 25-hydroxyvitamin D
in NHANES (4). Previous expert panels reviewed NHANES
measurement procedures in detail, and the 2009 roundtable also
reviewed the relevant reference methods and materials that the
National Institute of Standards and Technology (NIST) had re-
cently made available or was developing. NHANES recently in-
corporated NIST reference methods and materials for several
folate- and vitamin B-12–related biomarkers as well as for serum
25-hydroxyvitamin D (2–4). The 2009 roundtable found these
referencemethodsandmaterialstobeaninvaluableresourceforthe
resolution of longstanding NHANES measurement procedure
comparability and accuracy problems (4). The PC, which antici-
patedasimilarneedtoreviewtheseissuesbythe2010roundtable,
scheduled presentations by Karen Phinney on the NISTreference
materialsandmethodsforserumfolates,vitaminB-12,MMA,and
tHcy (Table 2). As with the presentations on the NHANES mea-
surement procedures, the articles in this supplement that describe
the roundtable’s review include the presentations on the NIST
reference methods and materials (2, 3).
The 2009 roundtable experts (4), like their 2010 counterparts
(TableS1availableunder“Supplementaldata”intheonlineissue),
represented a broad range of expertise. Although this range of
expertise added useful breadth and provided the opportunity
tointegrateconceptsfromarangeofscientiﬁcperspectives, an
assessment of the 2009 roundtable’s discussions found that the
group’s dialogue would have beneﬁted from some general back-
ground information to facilitate a common understanding of the
wide-ranging concepts and terminologies involved in the round-
table review. Therefore, planners of the 2010 roundtable included
several background presentations in the agenda. These presenta-
tions reﬂected the individual perspectives of the presenters.
Theﬁrst2backgroundpresentations,byElizabethYetleyofthe
ODSandJosephMassaroofBostonUniversity(Table2),covered
the history and use of folate and vitamin B-12 biomarkers in
TABLE 2
Roundtable agenda
1
Agenda item Reference
General background information
History and use of folate and vitamin B-12 biomarkers in NHANES: implications for NHANES measurements—Elizabeth A Yetley (1)
Statistical approaches of the chemist: implications for NHANES measurements—Joseph Massaro (1)
Metrological principles for standardization of laboratory measurement procedures: implications for measurement of biomarkers of folate
and vitamin B-12 in NHANES—John H Eckfeldt
(5)
Folate status biomarkers
The history of folate assessment and its implications for measurement of biomarkers of folate status in NHANES—Barry Shane (6)
Measures of serum and RBC folate in NHANES—Christine M Pfeiffer (2)
Comparison of serum and RBC folate MA results, NHANES 2007–2008—Christine M Pfeiffer (9)
Measurement of serum 5-MTHF and FA in NHANES 2001–2002—Jacob Selhub (10)
Measurement of folate vitamers in serum and whole blood with LC-MS/MS—Christine M Pfeiffer (2)
Reference methods, materials, and calibrators for 5-MTHF, FA, total folate, and 5-FTHF in serum—Karen W Phinney (2)
Population monitoring of serum 5-MTHF and FA in NHANES—Regan L Bailey (11)
Roundtable discussion: measurement of total serum and RBC folate, serum 5-MTHF and FA, and other folate vitamers in NHANES (2)
Vitamin B-12 status biomarkers
History of vitamin B-12 assessment and its implications for measurement of biomarkers of vitamin B-12 status in NHANES—Ralph
Carmel
(7)
Measurement of serum vitamin B-12 in NHANES—Christine M Pfeiffer (3)
Measurement of MMA in NHANES—Christine M Pfeiffer (3)
Reference methods, standards, calibrators for serum vitamin B-12 and MMA—Karen W Phinney (3)
MMA as an NHANES biomarker of vitamin B-12 status—Regan L Bailey (3)
Measurement of holoTC in population-based studies—Ebba Nexo (8)
Roundtable discussion: measurement of biomarkers of vitamin B-12 status in NHANES (3)
Measurement of tHcy in NHANES—Christine M Pfeiffer (3)
Reference materials, reference methods, and calibrators for tHcy in serum—Karen W Phinney (3)
Roundtable discussion: measurement of tHcy in NHANES (3)
1 RBC, red blood cell; MA, microbiological assay; 5-MTHF, 5-methyltetrahydrofolic acid; FA, folic acid (also referred to as unmetabolized folic acid); LC-
MS/MS, liquid chromatography–tandem mass spectrometry; 5-FTHF, 5 formyltetrahydrofolic acid; MMA, methylmalonic acid; holoTC, holotranscobalamin;
tHcy, total homocysteine.
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panelsidentiﬁedwhentheyexaminedfolate-relatedbiomarkersin
NHANES, and statistical issues of key importance to NHANES
users. The article by Yetley and Johnson (1) summarizes these pre-
sentations. Comparability of measurementprocedures across survey
periods and the relevance of commonly used status cutoffs to the
NHANES context have been a persistent problem for past expert
panels, and the PC anticipated that these issues would also chal-
lenge the 2010 roundtable. In addition, the PC thought that the
roundtable should be aware of the statistical challenges involved
in ensuring that biomarker measurements are accurate at the tails
of the biomarker distributions as well as at the means.
Because ofthe availabilityanddevelopment ofNISTreference
methods and standards and the usefulness of these standards for
NHANES biomarker data that the 2009 roundtable had identiﬁed
(4), the PC scheduled a presentation by John Eckfeldt of the
UniversityofMinnesota.Eckfeldtdiscussedtheevolvingconcepts
anduseoftraceabilityapproachesbyclinicallaboratoriestoensure
accuracyandcomparabilityofresultsacrosstime,laboratories,and
measurement procedures (Table 2) (5). These concepts were un-
familiartomanypanelistsonthe2009roundtablebutplayedacritical
role in the group’s review and conclusions. Therefore, the PC
deemedtheinclusionofthisbackgroundinformationtobeessential
for the 2010 roundtable.
Another lesson learned from the 2009 roundtablewas the need
forbackgroundinformationonthehistoryofthemeasurementand
assessment of folate and vitamin B-12 status. Commonly used
cutoffs of adequacy depend on the measurement method, so un-
derstanding their derivation was important for the roundtable’s
evaluation of current and future NHANES measurement proce-
dures. Moreover, as measurement procedures have evolved, ex-
perts have obtained insights into measurement accuracy and
potential biases or interferences. Understanding what the various
biomarkers measure and the relevance of the approaches that
experts have used to derive cutoffs of adequacy can inform an
evaluationoftheirusefulnessforfutureNHANES.Toprovidethese
types of background information to the roundtable panel, the PC
askedBarryShane(6)oftheUniversityofCalifornia,Berkeley,to
discuss the history of folate measurement and assessment, and
RalphCarmel(7)ofWeillMedicalCollegeofCornellUniversityto
do the same for vitamin B-12 (Table 2).
Finally, part of the roundtable’s charge was to consider which
biomarkers and associated measurement procedures to include in
futureNHANES.Publichealthconcernsrelatedtofolatestatusare
currently changing from inadequacy to overages and possible
adverseeffects.ThePCthereforerecommendedthattheroundtable
reviewthepotentialusefulnessoftheinclusionofmeasuresoffolate
vitamers in future NHANES and consider available measurement
procedures for their possible use. Because Jacob Selhub’s group at
Tufts University had measured folate vitamers from surplus sera
fromNHANES,thePCaskedSelhubtodescribethe measurement
procedureshisgroupusedforthatspecialresearchproject(Table2)
(10). After it learned that Pfeiffer’s group was evaluating a liquid
chromatography–tandem mass spectrometry (LC-MS/MS) pro-
cedureformeasurementoffolatevitamers,thePCaskedPfeifferto
describe the measurement procedure she used (2). To help the
roundtableunderstandthepotentialpublichealthramiﬁcationsofthe
measurementoffolatevitamersinfutureNHANES,ReganBaileyof
ODS described her population-based results with the use of the
NHANES 2001–2002 serum folic acid (also referred to as un-
metabolized folic acid) data that Tufts University had generated in
a special surplus sera research project (Table 1) (11).
The roundtable also considered potential issues for the as-
sessmentofvitaminB-12statusinthefuture.Becauseofincreased
interest in the measurement of holotranscobalamin in clinical and
research settings, the PC asked the roundtable to review the possi-
ble inclusion of this measurement procedure in future NHANES.
Ebba Nexo of Aarhus University Hospital in Denmark presented
backgroundinformationonthedevelopmentandusefulnessofthis
measure for population-based surveys (Table 2) (8). Carmel also
coveredthistopicbrieﬂy,fromasomewhatdifferentperspective,in
hisbackgroundinformation(7).Tohelptheroundtableevaluatethe
usefulness of vitamin B-12 status data to NHANES users, Bailey
used data from NHANES 1999–2004 to evaluate the population-
basedresultsofthecombinationofserumvitaminB-12andMMA
to assess vitamin B-12 status (3).
KEY POINTS FROM THE ROUNDTABLE DIALOGUE
TheODSandtheDivisionofHealthandNutritionExamination
Surveys charged the roundtable with identiﬁcation of the key
scientiﬁcissuesanddiscussionoftheprosandconsoftheseissues
butnotwiththemakingofrecommendations.Withlimitedtimefor
dialogue, the roundtable focused its attention on the issues that
members identiﬁed as most critical for the folate- and vitamin B-
12–related biomarkers in NHANES (2, 3). Therefore, the round-
table’sdialoguedidnotcoverallpossibletopicsandthegroupdid
not necessarily take time to resolve differences of opinion in the
background presentations. In some cases, the roundtable ach-
ievedgeneralagreementonanissue;inothercases,groupmembers
expressed different perspectives, which the dialogue summaries
capture.
ForbothfolateandvitaminB-12,theissuesthathadplaguedpast
expert panels also caught the attention of the 2010 roundtable: 1)
the interactions of measurement procedures and cutoffs of ade-
quacy, 2) the effect of changes in measurement procedures on
time-trend analysis, 3) the public health importance of various
measures,and4)theuseofevolvingsciencetoimproveNHANES
measurement procedures and interpretability. In addition, like the
2009 roundtable(4), the 2010roundtableacknowledged theurgent
need to ensure accurate NHANES biomarker measurements
through the application of traceability approaches with the use of
NISTand other external reference materials.
Folate-related background issues
The roundtable’s discussions focused on measurement and
biomarker issues (Table 3). In general, the roundtable agreed that
the MA is the traditional gold standard against which to evaluate
other measurement procedures (2, 6). It is also the basis for
currently used cutoffs of adequacy. On the basis of published lit-
erature that shows substantially lower results with the use of ra-
dioimmunoassay procedures compared with MA, the roundtable
was not surprised by the marked differences between the Bio-Rad
Quantaphase II (Bio-Rad Laboratories, Hercules, CA) and the MA
procedures that Pfeiffer described. The roundtable agreed that an
adjustment equation based on a crossover study was necessary for
time-trend evaluations.
The roundtable’s review of the NCEH data that showed close
agreement between the LC-MS/MS and MA measurement
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suggestion to base serum folate measures in future NHANES on
the LC-MS/MS procedure, which includes measurement of se-
rum vitamers. When the roundtable learned of the success of
the NCEH’s LC-MS/MS procedure for the measurement of
serum total folates and some folate vitamers, it did not ﬁnd it
necessarytoalsoconsiderothermeasurementprocedures,suchas
the afﬁnity HPLC measurement procedure that Selhub described
(10). However, Shane noted the potential usefulness of the HPLC
method for laboratories that lack LC-MS/MS facilities (6). The
situationforRBC folates wasless clear.LC-MS/MSresults differ
from MA results by ’25%. The roundtable therefore agreed that
the use of the LC-MS/MS procedure for measurement of RBC
folates requires further research before future NHANES can
measure RBC folates by LC-MS/MS procedures.
The roundtable spent considerable time in a discussion about
whether future NHANES need to measure both serum and RBC
folateandifNHANESonlymeasuresoneofthese,whichoneisbest.
Afterconsiderablediscussion,thegroupdecidedthateitherserumor
RBC folate measures would be useful for future NHANES.
Vitamin B-12–related background issues
Because it was generally satisﬁed with the NCEH’s handling
of measurement procedure issues for vitamin B-12–related bio-
markers, the roundtable turned its attention to reasons to reinstate
vitaminB-12biomarkersinfutureNHANESand,ifNHANESdoes
measurevitaminB-12biomarkersinthefuture,whichbiomarkers
the surveys should measure (Table 4) (3). No NHANES since
NHANES 2006 has measured any of these biomarkers. The
roundtableagreedwithCarmelaboutthelackofconﬁrmationthat
subclinicalvitaminB-12deﬁciency(alsoreferredtoassubclinical
cobalamindeﬁciencyorSCCD),thepredominantformofvitamin
B-12 inadequacy in the US population, presents a public health
concern (7). However, roundtable members also noted concerns
that observational studies have raised about possible adverse ef-
fects, and emphasized the need for further investigation of these
effects, particularly in clinical trials. The roundtable identiﬁed
several factors that may justify the reinstatement of vitamin B-12
measures in future NHANES.
The roundtable generally agreed that NHANES would pref-
erably measure 2 vitamin B-12 biomarkers because of prob-
lems with sensitivity and speciﬁcity of any single biomarker (3).
If NHANES includes 2 measures, it would be useful if one was
a measure of circulating concentrations of vitamin B-12 (ie,
serum vitamin B-12 or holotranscobalamin) and one a functional
measure of vitamin B-12 inadequacy (ie, plasma MMA or tHcy).
The roundtable agreed that, although holotranscobalamin holds
promise for a more meaningful measure of circulating vitamin
B-12 than does serum vitamin B-12, sufﬁcient experience is not
available for the measurement and use of holotranscobalamin to
include it as the sole measure of circulating concentrations of
vitamin B-12. MMA was preferable to tHcy because of its
speciﬁcity for vitamin B-12 inadequacies.
Insummary,the2010roundtableagreedthatamovetowardthe
development and use of traceability approaches is the best way to
deal with accuracy and comparability problems in NHANES
biomarkermeasurements.Anurgentneedexistsfortrialsthatrelate
accuratelymeasurednutrientbiomarkerdatatoclinicaloutcomesto
identify cutoffs of nutrient adequacy. Either serum or RBC folate
would be useful for future NHANES. The use of the LC-MS/MS
procedureformeasurementofRBCfolatesrequiresfurtherresearch
TABLE 3
Roundtable dialogue: measurement of biomarkers of folate status in NHANES
1
Measurement and biomarker issues
Measurement of total folate is complex because of numerous folate derivatives that exist in different oxidation states, one-carbon substitutions, and
polyglutamate chain lengths.
MAs are the gold standard because they measure all biologically active forms of folate equally but do not measure degradation products that lack biological
activity.
The Bio-Rad Quantaphase II procedure (Bio-Rad Laboratories, Hercules, CA) that NHANES 1991–1994 and NHANES 1999–2006 used produced serum
and RBC folate results that were, on average, 29% lower for serum and 45% lower for RBC than the MA that NHANES 2007–2010 used. These
differences will require adjustment equations to evaluate time trends.
The LC-MS/MS results for serum folate are in close agreement with the MA results, and future NHANES can therefore use LC-MS/MS results to assess
both serum total folate and serum folate vitamers.
The LC-MS/MS measurement procedure for RBC folate produces results that are 25% lower than the MA procedure and therefore its use for future
NHANES is premature until researchers identify reasons for these differences.
The JCTLM lists as reference methods the LC–MS/MS measurement procedures that NIST developed and uses and the NCEH/CDC methods for serum
5-MTHF, 5-FTHF, and THF.
NIST reference materials for serum 5-MTHF, folic acid, total folate, and 5-FTHF are currently available, and NHANES has incorporated these materials
into its measurements of these biomarkers.
The historical advantage of RBC folate (as an indicator of long-term status) over serum folate (as an indicator of recent intakes) for assessment of folate
status may not be critical for NHANES because the general population does not drastically change daily intakes. Future surveys may not need to
measure both.
A major advantage of serum folate is its relevance to clinical and research results because of its current wide use in these settings.
A major advantage of RBC folate is its usefulness for evaluation of the effects of high folate intakes on vitamin B-12–insufﬁcient patients.
With the focus of public health concerns changing from inadequate folate intakes to excessive intakes, information on folate vitamers would be usefuli n
future NHANES.
1 Data from reference 2. MA, microbiological assay; RBC, red blood cell; LC-MS/MS, isotope dilution liquid chromatography–tandem mass spectrom-
etry; NIST, National Institute of Standards and Technology; NCEH/CDC, National Center for Environmental Health/Centers for Disease Control and
Prevention; 5-MTHF, 5-methyltetrahydrofolic acid; 5-FTHF, 5-formyltetrahydrofolic acid; THF, tetrahydrofolic acid; JCTLM, Joint Committee on Trace-
ability in Laboratory Medicine.
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folates,butthisprocedurecannowbeusedtomeasureserumfolate.If
NHANES reinstates vitamin B-12 biomarker measurement, the
surveys should include at least one measure of circulating con-
centrationsofvitaminB-12 and one functional measure of vitamin
B-12 inadequacy.
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TABLE 4
Roundtable dialogue: measurement of biomarkers of vitamin B-12 status in NHANES
1
Measurement and biomarker issues
Reliable measurement procedures are available for serum vitamin B-12, plasma MMA, and tHcy.
NIST reference materials are available or in development for vitamin B-12, MMA, and tHcy. Development of reference materials with certiﬁed values for
total cobalamin is of higher priority than characterization of vitamin B-12 species at this time.
JCTLM lists the NIST GC-MS and LC-MS/MS measurement procedures for tHcy as reference methods.
Future NHANES should reinstate measurement of biomarkers of vitamin B-12 status.
Uncertainty exists about whether subclinical (mild, asymptomatic) vitamin B-12 deﬁciency
2 is a public health concern. Subclinical vitamin B-12 deﬁciency
affects a larger percentage of the population than does clinical vitamin B-12 deﬁciency.
Problems with sensitivity and speciﬁcity of individual biomarkers of vitamin B-12 status underscore the need for the inclusion of at least one biomarker of
circulating vitamin B-12 (serum vitamin B-12 or holoTC) and one functional biomarker (MMA or tHcy) in NHANES.
Inclusion of serum vitamin B-12 and plasma MMA measures in future NHANES would provide continuity with past NHANES.
Measurement of tHcy as an indicator of vitamin B-12 status has little value for future NHANES if the surveys include other measures of vitamin B-12
status.
1 Data from reference 3. MMA, methylmalonic acid; tHcy, total homocysteine; NIST, National Institute of Standards and Technology; holoTC,
holotranscobalamin; JCTLM, Joint Committee for Traceability in Laboratory Medicine; GC-MS, gas chromatography–mass spectrometry; LC-MS/MS, liquid
chromatography–tandem mass spectrometry.
2 Also referred to as subclinical cobalamin deﬁciency or SCCD (7).
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